We are pleased to announce the launch of a new CorEvitas clinical registry in Adolescent Alopecia Areata (AA). This registry, which is open to enrollment, addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of adolescent patients with AA.
The new registry will collect detailed prospective data, including the incidence of safety events of interest, medication utilization patterns and the comparative safety and effectiveness of treatments. It will also gather data on the history of AA in adolescents and the growth and development over time of adolescent AA patients undergoing treatment with new therapies.
Read the press release, here.
To find out more about the registry, including how to enroll, here.